In the not-too-distant future, several new combination therapies are expected, and they should represent an improvement not only in effectiveness, but in safety as well.
Results of a prospective study consisting of more than 105,000 women have shown "it is unlikely that stress is implicated in causation of breast cancer."
A pooled analysis of 3 combination drug regimens used to treat refractory/relapsed multiple myeloma reaffirms their safety, but does little to distinguish which approach works best.
Identifying and preventing drug-related toxicities with new combination therapies are paramount for both outcomes and quality of life issues.
Sexual function scores do not appear to differ between the 2 groups at 6 weeks or 12 weeks post-surgery, and no significant differences were found for bowel quality of life or pathological outcomes.
Humans can tolerate tumors in large or paired organs more easily than in small, critical organs, and the larger organs may therefore have evolved fewer mechanisms to defend against cancerous cells.
ASCO and the Society of Gynecologic Oncology jointly issued new clinical practice guidelines for the treatment of patients with ovarian cancer.
Q&A With Emmanuel Antonarakis, MD: AR-V7 "Liquid Biopsy" Can Avoid Unneeded Treatment, Curb Health Care Costs
AR-V7 has been implicated in metastatic prostate tumor resistance to the androgen-receptor signaling (ARS) blockers abiraterone and enzalutamide.
Researchers at Johns Hopkins identified genes involved in tumor cell metabolism that may predict which patients with renal cell carcinoma are unlikely to respond to treatment with nivolumab.
Cancer Therapy Advisor interviewed Lynn M. Schuchter, MD, to discuss the questions frequently asked by patients with melanoma during both the diagnosis and treatment phases of care.
Understanding the signaling pathways of cancer stem cells could hold promise for treating resistant forms of cancer.
The therapeutic landscape of renal cell carcinoma (RCC) has improved over the last 10 years, and greater advances are expected.
As our aging workforce expands, a decreasing number of young investigators are applying for National Institute of Health (NIH) R01-equivalent grants.
Invasive basal cell carcinoma arises only from epidermal stem cells, according to a study published in Nature.
Readers should look for "anything that adds uncertainty to the analysis, including uncertainty in the measurements, differences in dropout rates among arms, missing data, and how they were handled in the analysis."
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Should We Abandon PSA Testing Or Make it More Targeted?
- PD-1, PD-L1 Agents Rarely Induce Durable Remissions in Uveal Melanoma
- A Call for a New Collaboration to Cure Melanoma
- Age and Acute Myeloid Leukemia: A Review of Current Literature
- Scan-associated Distress May Be Persistent for Patients With NSCLC
- Breast Cancer (Invasive) Treatment Regimens
- TRUS-biopsy Poorly Detects Prostate Cancer
- Model Predicts That Healthful Lifestyle Benefits Women at Risk of Breast Cancer
- Mental Disorder Risk High Among Patients With Cancer During Treatment and Before Diagnosis
- Cobimetinib Plus Atezolizumab Active in Colorectal Cancer
- PAP Series: Patient Assistance Programs "Culprits" of Rising Drug Prices
- Multiple Myeloma: Finding Resources and Support
- Selumetinib Fails to Meet PFS End Point in KRAS-mutant NSCLC
- Trial of Brentuximab Vedotin in CD30+ CTCL Meets Primary End Point
- Positive Optimization of Patient Expectations Before Treatment Recommended